二十五味珊瑚丸联合左乙拉西坦治疗癫痫的临床研究

目的探讨二十五味珊瑚丸联合左乙拉西坦片治疗癫痫的临床疗效。方法选取2015年4月至2016年10月中国人民解放军第二五四医院、天津市环湖医院收治的癫痫患者30例为研究对象,按照序列号法将患者随机分为对照组和治疗组,每组各30例。对照组餐后口服左乙拉西坦片,起始剂量500 mg/次,2次/d,一周后加至1 000 mg/次,2次/d。治疗组在对照组治疗基础上口服二十五味珊瑚丸,1 g/次,1次/d。两组患者均连续治疗3个月。观察两组的临床疗效,比较两组的淋巴细胞亚群水平、炎症因子水平、癫痫发作频率。结果治疗后,对照组和治疗组的总有效率分别为73.33%、93.33%,两组比较差异有统计学意义(P0.05)。治疗后,两组CD3~+、CD4~+、CD4~+/CD8~+水平明显升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗组淋巴细胞亚群水平明显高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组可溶性细胞间黏附分子-1(s ICAM-1)、白细胞介素-6(IL-6)、C反应蛋白(CRP)水平均明显降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组炎症因子水平明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组癫痫发作频率明显降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组癫痫发作频率明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论二十五味珊瑚丸联合左乙拉西坦片治疗癫痫具有较好的临床疗效,可减少癫痫发作频率,改善患者免疫功能,减轻炎症反应,具有一定的临床推广应用价值。

Clinical study on Ershiwuwei Shanhu Pills combined with levetiracetam in treatment of epilepsy

Objective To investigate the effect of Ershiwuwei Shanhu Pills combined with Levetiracetam Tablets in treatment of epilepsy. Methods Patients (60 cases) with epilepsy in the No. 254 Hospital of PLA and Tianjin Huanhu Hospital from April 2015 to October 2016 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were po administered with Levetiracetam Tablets after meal with starting dosage 500 mg/time, twice daily, after 1 week, dose increased to 1 000 mg/time, twice daily. Patients in the treatment group were po administered with Ershiwuwei Shanhu Pills on the basis of the control group, 1 g/time, once daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the frequency of the levels of lymphocyte subgroup, the levels of inflammatory factors, and frequency of epileptic seizures in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.33% and 93.33%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the levels of lymphocyte subgroup in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of sICAM-1, IL-6, and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the frequencies of epileptic seizures in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the frequencies of epileptic seizures in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Ershiwuwei Shanhu Pills combined with Levetiracetam Tablets has clinical curative effect in treatment of epilepsy, can decrease the frequency of epileptic seizures, improve the immune function of patients, and reduce the inflammatory response, which has a certain clinical application value.